Vectorite Biomedical Inc. (TPEX:4170)

Vectorite Biomedical Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	54.81	61.41	57.77	55.85	42.91	28.77
Revenue Growth	-10.74%	6.29%	3.43%	30.15%	49.16%	17.22%
Gross Profit Gross Profit Growth	17.04	21.68	16.97	16.42	0.71	-2.47
Operating Income Operating Income Growth	-23.18	-21.91	-25.97	-16.13	-30.54	-42.43
Net Income Net Income Growth	118.22	96.17	-40.05	-6.6	-26.41	8.36
Earnings Per Share EPS Growth	2.65	2.19	-0.92	-0.15	-0.60	0.19
EPS Growth	21.05%	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Taiwan Taiwan Growth	60.56	57.66	55.85	42.91	28.76
China China Growth	0.85	0.11	-	-	-
Total Total Growth	61.41	57.77	55.85	42.91	28.77

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	166.32	170.61	184.9	203.67	213.52	239.38
Total Debt Total Debt Growth	0.3	0.39	-	-	-	-
Net Cash (Debt) Net Cash Growth	166.02	170.23	184.9	203.67	213.52	239.38
Net Cash Growth	-2.47%	-7.94%	-9.21%	-4.61%	-10.80%	167.28%
Net Cash Per Share Net Cash Per Share Growth	3.72	3.87	4.23	4.65	4.88	5.57

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-4.76	-5.79	-11.51	1.3	14.7	-65.79
Capital Expenditures CapEx Growth	-4	-4	-2.84	-4.76	-0.89	-1.8
Free Cash Flow Free Cash Flow Growth	-8.76	-9.78	-14.35	-3.46	13.81	-67.59
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	31.09%	35.31%	29.37%	29.40%	1.65%	-8.60%
Operating Margin	-42.29%	-35.68%	-44.96%	-28.88%	-71.16%	-147.47%
Pretax Margin	219.70%	156.57%	-69.37%	-11.87%	-61.64%	28.95%
Profit Margin	215.70%	156.62%	-69.33%	-11.82%	-61.55%	29.05%
FCF Margin	-15.98%	-15.93%	-24.84%	-6.19%	32.19%	-234.93%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 26, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	4.79	6.37	-	-	-	74.32
P/FCF Ratio	-	-	-	-	44.96	-
PS Ratio	10.14	9.98	10.99	16.73	14.47	21.59

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 26, 2026

Data Sources Report a data error